Anti-mullerian hormone receptor binding peptides

A method of modulating folliculogenesis in a subject, the method comprising administering to the subject an effective amount of an AMH-R2 binding peptide,

• wherein the AMH-R2 binding peptide comprises:
• (i) any one of the amino acid sequences set forth as SEQ ID NOS:
• 1-20;
• or
• (ii) a variant of any one of the amino acid sequences set forth as SEQ ID NOS:
• 1-20, wherein the variant comprises no more than two amino acid substitutions relative to the corresponding amino acid sequence of SEQ ID NOS:
• 1-20,
• thereby modulating folliculogenesis in the subject.

A method of inhibiting premature follicle activation in a subject undergoing ovarian tissue transplantation or whole ovary transplantation, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an AMH-R2 binding peptide, wherein the AMH-R2 binding peptide comprises:

• (i) any one of the amino acid sequences set forth as SEQ ID NOS:
• 1-20;
• or
• (ii) a variant of any one of the amino acid sequences set forth as SEQ ID NOS:
• 1-20, wherein the variant comprises no more than two amino acid substitutions relative to the corresponding amino acid sequence of SEQ ID NOS:
• 1-20.